- Home
- PLG vs ABEO Comparison
PLG vs ABEO Comparison
Compare PLG & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLG | ABEO |
|---|---|---|
| Founded | 2000 | 1974 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 281.0M |
| IPO Year | N/A | 1980 |
Fundamental Metrics
Financial Performance| Metric | PLG | ABEO |
|---|---|---|
| Price | $2.46 | $4.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 2.0M | ★ 2.4M |
| Earning Date | 01-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | N/A | ★ $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,590.36 |
| P/E Ratio | ★ N/A | $3.79 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $3.93 |
| 52 Week High | $3.36 | $7.54 |
Technical Indicators
Market Signals| Indicator | PLG | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 51.76 |
| Support Level | $2.32 | $4.53 |
| Resistance Level | $2.49 | $4.92 |
| Average True Range (ATR) | 0.15 | 0.25 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 88.31 | 69.80 |
Price Performance
Historical ComparisonAbout PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.